LEAP-004 Update: Lenvatinib Plus Pembrolizumab for Advanced Melanoma Following Progression on a PD-1/PD-L1 Inhibitor

June 4-8, 2021; Online at https://conferences.asco.org/am
Updated data from the LEAP 004 trial of lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progression on anti–PD-1/PD-L1 therapy resulted in durable responses and no new safety signals.
Format: Microsoft PowerPoint (.ppt)
File Size: 514 KB
Released: June 9, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Related Content

Experts Michael A. Davies, MD, PhD, and Jeffrey S. Weber, MD, PhD, review key data in melanoma presented at the 2022 Society for Melanoma Research Annual Congress, from Clinical Care Options (CCO)

Michael A. Davies, MD, PhD Jeffrey S. Weber, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 19, 2022 Expired: December 18, 2023

Dr Michael Davies highlights key studies presented at the 2022 Society for Melanoma Research Annual Congress in this commentary from Clinical Care Options (CCO)

Michael A. Davies, MD, PhD Released: November 17, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Download slides on selected studies from the 2022 Society for Melanoma Research Annual Congress, as reported by Clinical Care Options (CCO)

Released: October 31, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings